Business
CareDx to Report First Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of
About this update from Caredx, Inc.
[{"type":"text","content":" BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.\n\n\nIndividuals interested in listening to the conference call may do so by dialing 1-800-732-8470 for domestic callers or 1-212-231-2912 for international callers. Please reference Conference ID: 22026935. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.\n\n\nAbout CareDx – The Transplant Company\n\n\nCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230508005264/en/\n\nCareDx, Inc.\nInvestor Relations\nGreg Chodaczek\[email protected]\n\n\nSource: CareDx, Inc.","length":3726,"tagName":"div"}]